Neurent Medical Raises $74M for Chronic Rhinitis Treatment

Jan de Vries · 2026-02-12

Big news from the world of medical technology. Neurent Medical, an Irish company based in Galway, just closed a massive Series C funding round. They raised a whopping $74 million to push their chronic rhinitis solution, called NEUROMARK, further into the market. It's a significant vote of confidence from some major players. The round was led by MVM Partners, with Sofinnova Partners jumping in as a significant new investor. The company's existing backers—EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland—all doubled down with continued support. ### What This Funding Means for Patients So, what's the big deal? For the millions of people struggling with chronic rhinitis, this could be a game-changer. Brian Shields, the CEO of Neurent Medical, put it simply. He said this cash infusion will help them expand commercially and finally get NEUROMARK into the hands of the doctors and patients who've been waiting for a better option. Think about it. Chronic rhinitis isn't just a minor sniffle. It's persistent congestion, a constantly runny nose, sneezing fits, and that annoying postnasal drip. It wears you down and can seriously tank your quality of life. Current treatments often just manage symptoms. NEUROMARK aims to tackle the root cause. ### How NEUROMARK Works The technology is pretty clever. It's a minimally invasive system that uses something called Impedance Controlled Radiofrequency. In plain English, it gently targets the overactive nerves in the back of your nose that are causing all the trouble. The system gives doctors real-time feedback during the procedure, which means more control and predictability. The goal is durable relief with minimal downtime. It's designed to be a one-and-done kind of treatment, not something you have to keep going back for. ### A Hot Market for HealthTech This funding didn't happen in a vacuum. The European HealthTech scene is buzzing right now. Just look at some of the other recent raises: - SamanTree Medical in Belgium got $21.2 million for a surgical imaging device. - Recare in Berlin secured $39.2 million to scale its AI hospital platform. - Smaller, but still notable, rounds like PIUR IMAGING ($5.9 million) and Juisci ($5.8 million) show investor appetite is strong across the board. Neurent's $74 million haul sits at the very top of that heap. It tells you that investors are especially bullish on companies with clinically validated devices for chronic conditions where good options are scarce. Kyle Dempsey, a Partner at MVM, nailed the reason why. "Millions of patients suffer," he said, "and this represents a powerful tool to provide proven relief." He called NEUROMARK a "best-in-class solution" that's setting a new standard. ### Looking to the Future This isn't the end of the road, either. The new investors see a lot of potential beyond just chronic rhinitis. Cedric Moreau from Sofinnova Partners pointed to a "growing body of clinical evidence" and hinted at expanding the platform into other medical areas down the line. Both Dempsey and Moreau have also joined Neurent Medical's Board of Directors, bringing their expertise to guide this next phase of growth. Founded back in 2015, Neurent Medical has been quietly working on this problem for nearly a decade. This $74 million milestone is more than just money in the bank. It's fuel for their mission to transform how we treat chronic sinus inflammation, offering hope for a long-term solution where before there was often just temporary management.